Effect of Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing Coronary Artery bypass graft surgery (ERICCA study): a multicentre double-blind randomised controlled clinical trial

Derek J Hausenloy,1,2,3,4† Luciano Candilio,1† Richard Evans,5 Cono Ariti,5 David P Jenkins,6 Shyamsunder Kolvekar,7 Rosemary Knight,5 Gudrun Kunst,8 Christopher Laing,9 Jennifer M Nicholas,5 John Pepper,10 Steven Robertson,5 Maria Xenou,1 Timothy Clayton5 and Derek M Yellon1,2

1Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, UK
2National Institute for Health Research, University College London Hospitals Biomedical Research Centre, London, UK
3National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore
4Cardiovascular and Metabolic Disorders Program, Duke–National University of Singapore, Singapore
5Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK
6Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge, UK
7The Heart Hospital, University College London Hospitals NHS Foundation Trust, London, UK
8Department of Anaesthetics and Pain Therapy, King’s College London and King’s College Hospital, London, UK
9University College London Centre for Nephrology, Royal Free Hospital, London, UK
10National Institute for Health Research Cardiovascular Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust, London, UK

*Corresponding author
†Derek J Hausenloy and Luciano Candilio are joint first authors

Declared competing interests of authors: Derek J Hausenloy and Timothy Clayton report grants from the British Heart Foundation during the conduct of the study.
Scientific summary

The ERICCA study
Efficacy and Mechanism Evaluation 2016; Vol. 3: No. 4
DOI: 10.3310/eme03040

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the world. Coronary artery bypass graft (CABG) surgery is the revascularisation strategy of choice, particularly in patients with complex CAD or diabetes and/or when aged > 65 years. More recently, higher-risk patients are being operated on because of the ageing population, the more complex CAD being operated on, coexistent comorbidities (including diabetes and hypertension) and the increasing occurrence of combined valve surgery. All of these factors together increase perioperative risk, with a significantly higher incidence of death, stroke and acute kidney injury (AKI) therefore seen in these patients. Another important implication of the increasing risk profile of subjects undergoing CABG surgery is the higher magnitude of perioperative myocardial injury (PMI), which has been recognised as being potentially attributable to a number of pathogenetic factors, the most important of which is ischaemia–reperfusion injury. Ischaemia–reperfusion injury is sustained as a consequence of intermittent aortic cross-clamping, intermittent or continuous administration of cardioplegia, or cross-clamp fibrillation. This can be measured using imaging diagnostic modalities and most importantly with the postoperative rise in serum concentrations of cardiac biomarkers, such as creatine kinase MB and troponin T or I. Studies have demonstrated that a postoperative increase in such cardiac biomarkers is associated with worse short- and long-term clinical outcomes, with increases in morbidity and mortality. Therefore, novel cardioprotective strategies are required to protect these patients to reduce PMI and the incidence of potentially devastating complications including stroke, AKI and death.

In this regard, remote ischaemic preconditioning (RIPC), which describes the phenomenon by which brief episodes of transient ischaemia–reperfusion of an organ or tissue distant from another organ or tissue are able to protect the latter from ischaemia–reperfusion, has emerged as a novel, non-invasive and low-cost intervention capable of reducing PMI in patients undergoing cardiac surgery and therefore improving short- and long-term clinical outcomes in these subjects. Since its description in an animal model by Przyklenk et al. in 1993 and its first application in healthy human volunteers by Kharbanda et al. in 2002, the concept of RIPC has been applied to different clinical settings including elective cardiac surgery, non-cardiac surgery, elective or primary percutaneous coronary intervention and organ transplantation (Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893–9; Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschitzky JA, et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 2002;106:2881–3). However, particularly in the context of elective CABG surgery, outcomes from randomised clinical trials have been often discordant and this could be for a number of reasons, including patient characteristics, the clinical setting and the use of concomitant medications. Crucially, the vast majority of these studies were relatively small proof-of-concept trials primarily investigating the potential effects of RIPC on PMI and only a much smaller proportion of studies assessed RIPC implications for clinical outcomes, a finding for which such studies were not sufficiently powered.

We therefore conducted a multicentre randomised sham controlled trial to investigate the effects of RIPC on clinical outcomes in higher-risk patients undergoing CABG surgery with or without valve surgery [the Effect of Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing Coronary Artery bypass graft surgery (ERICCA) trial].
Objectives

The specific research questions addressed in this trial were:

- Does RIPC improve the combined primary end point of death, revascularisation, stroke and myocardial infarction (MI) in higher-risk patients undergoing CABG surgery with or without valve surgery at 12 months post surgery?
- Does RIPC improve any of these clinical outcomes individually in higher-risk patients undergoing CABG surgery with or without valve surgery at 30 days and 12 months post surgery?
- Does RIPC improve PMI, AKI, inotrope requirement, intensive care and hospital stay duration and quality of life in higher-risk patients undergoing CABG surgery with or without valve surgery?

Methods

The ERICCA trial recruited 1612 higher-risk [euroSCORE (European System for Cardiac Operative Risk) of ≥ 5] patients undergoing CABG with or without valve surgery from 30 surgical centres in the UK.

Patients randomised to receive RIPC had a standard blood pressure cuff placed on the upper arm and inflated to 200 mmHg for 5 minutes and then deflated for 5 minutes, a cycle that was performed four times in total. The control group received simulated 5-minute inflations/deflations of a standard blood pressure cuff placed on the upper arm, a cycle that was repeated four times. These interventions were undertaken after the induction of anaesthesia.

The primary analysis compared the rate of major adverse cardiac and cerebrovascular events (MACCE) within 12 months between the RIPC arm and the sham control arm using Cox proportional hazards models. The same time-to-event methods were used to evaluate 30-day MACCE; components of 30-day and 12-month MACCE; and all-cause death at 12 months. To compare subgroups with regard to the effect of treatment on the incidence of MACCE, we included an interaction between treatment group and the subgroup variable in the time-to-event model. The primary analysis was conducted on an intention-to-treat (ITT) basis and included all participants regardless of whether the RIPC or sham control procedure was performed and whether or not CABG (with or without valve) surgery was performed. We also carried out a per-protocol (PP) analysis that was restricted to participants who received the RIPC and sham control protocols as specified and underwent CABG (with or without valve) surgery.

Results

Between April 2011 and March 2014, 1612 patients undergoing on-pump CABG (with or without valve) surgery with blood cardioplegia were recruited. The treatment groups (n = 811 sham control group, n = 801 in RIPC group) were well balanced in respect of both patient baseline characteristics and surgical details. Use of cardiovascular medications during follow-up was similar in the two treatment groups. There were very few participants lost to follow-up before 12 months [28 (3%) sham control group vs. 19 (2%) RIPC group]. All 1612 patients were included in the analysis of the primary outcome.

The proportion of participants with the MACCE primary end point within 12 months was similar between the groups [26.5% (n = 212) RIPC group vs. 27.7% (n = 225) control group; hazard ratio (HR) 0.95, 95% confidence interval (CI) 0.79 to 1.15; p = 0.58]. We found no difference between the groups in any of the individual components of MACCE (cardiovascular death, MI, stroke and coronary revascularisation).

The results of the PP analysis and ITT analyses were very similar, with little difference in the incidence of MACCE between the intervention groups. In the PP analysis 27.2% (n = 188/691) of participants in the RIPC group experienced MACCE within 12 months compared with 28.5% (n = 204/717) in the sham
control group (HR 0.95, 95% CI 0.78 to 1.16; \(p = 0.64\)). No evidence was identified that the effect of RIPC was different between any of the prespecified subgroups, including age, euroSCORE, cross-clamp and bypass times, left ventricular ejection function and diabetes.

In addition, multiple imputation analyses undertaken to account for missing data on the perioperative high-sensitivity troponin T (hsTnT) assay provided no evidence of a reduction in total hsTnT release in the 3 postoperative days (observed 2.0% reduction, 95% CI 19% reduction to 6% increase; \(p = 0.63\)).

Participants in the RIPC arm had a walk distance on the 6-minute walk test (6MWT) at 12 months that was 23.3 metres further than that of sham control participants (95% CI 2.2 to 44.4 metres); however, only 785 participants completed the 6MWT on one or more occasions and this finding should therefore be interpreted cautiously.

There was no evidence of any effect of RIPC on any of the other secondary end points, including the rate of the combined end point at 30 days, death within 12 months, postoperative atrial fibrillation, AKI, postoperative release of neutrophil gelatinase-associated lipocalin (a marker of renal injury) and duration of intensive care unit and hospital stay.

There was no difference in the rate of adverse events between the RIPC group and the control group, with 364 out of 801 cases (45.4%) compared with 354 out of 811 cases (43.6%) respectively. Understandably, 35 out of 736 patients in the RIPC group (4.8%) compared with 2 out of 760 patients in the sham group (0.3%) experienced skin petechiae at the time of the intervention, albeit with no long-term consequences. A similar proportion in the RIPC and sham control groups experienced adverse events at times other than during the RIPC/sham control intervention \(n = 318/811\) (39%) vs. \(n = 314/801\) (39%)): however, none of these events was considered to be related to the intervention.

Conclusions

Remote ischaemic preconditioning, consisting of four 5-minute cycles of ischaemia–reperfusion of the upper arm, did not improve clinical outcomes in higher-risk patients undergoing elective on-pump CABG with or without valve surgery.

It is possible that RIPC might provide beneficial effects in different clinical settings. In the context of ST segment elevation MI patients treated with primary percutaneous coronary intervention, the magnitude of PMI is substantially greater than for cardiac surgery; in this regard, the COND12 (Effect of RIC on Clinical Outcomes in STEMI Patients Undergoing pPCI)/ERIC-PPCI (Effect of Remote Ischaemic Conditioning on Clinical Outcomes in STEMI Patients Undergoing PPCI) trial [see www.clinicaltrials.gov: NCT01857414 and NCT02342522 (accessed 17 March 2016)] will investigate the effect of RIPC on major clinical outcomes in this group of patients. In addition, the recently completed REPAIR (REmote preconditioning for Protection Against Ischaemia–Reperfusion in renal transplantation) trial (ISRCTN30083294) found that RIPC using transient arm ischaemia–reperfusion preserved renal graft function at 12 months following renal transplantation. It is therefore crucial to continue to investigate the potential mechanisms underlying RIPC as this may facilitate the translation of this simple, non-invasive, risk-free, low-cost intervention into beneficial effects on patient outcomes.

Trial registration

This trial is registered as ClinicalTrials.gov NCT01247545.
Funding

This project was funded by the Efficacy and Mechanism Evaluation programme, a MRC and NIHR partnership, and the British Heart Foundation.
Efficacy and Mechanism Evaluation

ISSN 2050-4365 (Print)
ISSN 2050-4373 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/). Editorial contact: nihredit@southampton.ac.uk

The full EME archive is freely available to view online at www.journalslibrary.nihr.ac.uk/eme. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Efficacy and Mechanism Evaluation journal
Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme
The Efficacy and Mechanism Evaluation (EME) programme was set up in 2008 as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is broadly aimed at supporting 'science driven' studies with an expectation of substantial health gain and aims to support excellent clinical science with an ultimate view to improving health or patient care.

Its remit includes evaluations of new treatments, including therapeutics (small molecule and biologic), psychological interventions, public health, diagnostics and medical devices. Treatments or interventions intended to prevent disease are also included.

The EME programme supports laboratory based or similar studies that are embedded within the main study if relevant to the remit of the EME programme. Studies that use validated surrogate markers as indicators of health outcome are also considered.

For more information about the EME programme please visit the website: http://www.nets.nihr.ac.uk/programmes/eme

This report
The research reported in this issue of the journal was funded by the EME programme as project number 09/100/05. The contractual start date was in November 2010. The final report began editorial review in July 2015 and was accepted for publication in February 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2016. This work was produced by Hausenloy et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).